Primary Analysis Results of Novel BCL2 Inhibitor Sonrotoclax (BGB-11417) Monotherapy in Patients With Relapsed/Refractory B-Cell Malignancies

PF574

Caixia Li,[1] Keshu Zhou,[2] Jia Wei,[3] He Huang,[4] Peng Liu,[5] Hui Zhou,[6] Qingqing Cai,[7] Shenmiao Yang,[8] Yujun Dong,[9] Zhiyu Liang,[10] Zaixing Shi,[10] Remus Vezan,[11] Depei Wu[1]

[1]The First Affiliated Hospital of Soochow University, Suzhou, China; [2]Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; [3]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; [4]The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; [5]Affiliated Zhongshan Hospital of Fudan University, Shanghai, China; [6]Hunan Cancer Hospital, Changsha, China; [7]Sun Yat-sen University Cancer Center, Guangzhou, China; [8]Peking University People's Hospital, Beijing, China; [9]Peking University First Hospital, Beijing, China; [10]BeOne Medicines Ltd, Shanghai, China; [11]BeOne Medicines Ltd, San Carlos, CA, USA

CONCLUSIONS

- Sonrotoclax was well tolerated at all tested doses up to 640 mg in patients with R/R CLL/SLL and NHL
  - No cases of TLS were observed
  - Rates of discontinuation due to TEAEs were low
- Sonrotoclax demonstrated deep responses in patients with R/R CLL/SLL, with an ORR of 72.4% and a best blood uMRD4 rate of 41.4%
- Responses were observed in patients with R/R NHL, with an ORR of 20.0% and three patients achieving a CR
- Sonrotoclax is being evaluated as monotherapy in patients with R/R CLL/SLL in the BGB-11417-202 study and in combination with an anti-CD20 antibody in patients with R/R CLL in the CELESTIAL-RRCLL study

INTRODUCTION

- B-cell lymphoma 2 (BCL2) is frequently overexpressed in hematologic malignancies, which can lead to resistance to apoptosis[1]
- The first-generation BCL2 inhibitor venetoclax is an effective treatment for patients with B-cell malignancies; however, its clinical use can be limited by toxicity[2]
- Sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax, with a shorter half-life and no drug accumulation[3,4]
- Here, the safety and antitumor activity of sonrotoclax monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and R/R non-Hodgkin lymphoma (NHL) in the BGB-11417-102 study are presented

METHODS

- BGB-11417-102 (NCT04883957) is an open-label, phase 1 study of sonrotoclax monotherapy in patients with B-cell malignancies in China (**Figure 1**)
- Sonrotoclax was administered orally once daily, with ramp-up to the target dose to prevent potential risk of tumor lysis syndrome (TLS)

Figure 1. BGB-11417-102 Study Design



[a]Dose-limiting toxicities were assessed during dose ramp-up through day 21 at the target dose. [b]MRD was assessed in peripheral blood by flow cytometry every 24 weeks; undetectable MRD was defined as <1 CLL cell per 10^4 leukocytes.

Abbreviations: CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CT, computed tomography; DLBCL, diffuse large B-cell lymphoma; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; INV, investigator; iwCLL, International Workshop on CLL; MRD, measurable residual disease; MRI, magnetic resonance imaging; MTD, maximum tolerated dose; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetics; R/R, relapsed/refractory; RP2D, recommended phase 2 dose; TF, transformed; TLS, tumor lysis syndrome; TTR, time to response.

RESULTS

- As of August 23, 2024, 64 patients (CLL/SLL, n=29; NHL, n=35) had received sonrotoclax, and 16 (25%) remained on study treatment
- Median follow-up was 23.4 months (range, 1.5-35.7 months)
- Overall, 15 patients with CLL/SLL and 33 with NHL discontinued study treatment, primarily due to progressive disease
- Overall, the median age was 61.0 years and the median number of prior lines of therapy was 2 (**Table 1**)

Table 1. Demographic and Baseline Characteristics

Characteristic	CLL/SLL (n=29)	NHL (n=35)	All (N=64)
Age, median (range), years	61.0 (49-84)	59.0 (31-74)	61.0 (31-84)
Male sex, n (%)	20 (69.0)	15 (42.9)	35 (54.7)
ECOG PS			
0	11 (37.9)	12 (34.3)	23 (35.9)
1	12 (41.4)	19 (54.3)	31 (48.4)
2	6 (20.7)	4 (11.4)	10 (15.6)
Prior therapy			
No. of lines of prior therapy, median (range)	2.0 (1-7)	2.0 (1-7)	2.0 (1-7)
Prior BTK inhibitor, n (%)	15 (51.7)	13 (37.1)	28 (43.8)
Prior BTK inhibitor duration, median (range), months	6.2 (2.4-52.6)	4.5 (0.03-21.4)	4.8 (0.03-52.6)
Disease type, n (%)			
CLL	22 (75.9)	0	22 (34.4)
SLL	7 (24.1)	0	7 (10.9)
DLBCL	0	21 (60.0)	21 (32.8)
FL	0	7 (20.0)	7 (10.9)
MZL	0	4 (11.4)	4 (6.3)
Transformed B-cell NHL	0	3 (8.6)	3 (4.7)
Bulky disease, n (%)[a]	6 (20.7)	11 (31.4)	17 (26.6)
CLL/SLL risk characteristics at study entry, n/N (%)			
Binet stage C	7/14 (50.0)	NA	7/14 (50.0)
Unmutated IGHV	14/23 (60.9)	NA	14/23 (60.9)
del(17p)	2/28 (7.1)	NA	2/28 (7.1)
TP53 mutation	8/24 (33.3)	NA	8/24 (33.3)

[a]Any target lesion with a longest diameter of ≥5 cm.

Abbreviations: BTK, Bruton tyrosine kinase; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; IGHV, immunoglobulin heavy-chain variable region; MZL, marginal zone lymphoma; NA, not assessed; NHL, non-Hodgkin lymphoma; SLL, small lymphocytic lymphoma.

Safety

- Overall, 98.4% of patients experienced a treatment-emergent adverse event (TEAE) of any grade, and 62.5% experienced a grade ≥3 TEAE (**Table 2**)
  - The most common all-grade TEAEs were anemia and neutrophil count decreased (54.7% each)
  - The most common grade ≥3 TEAE was neutrophil count decreased (38%) (**Figure 2**)
- TEAEs led to treatment discontinuation in three patients (4.7%)
  - CLL: one patient (640 mg) with pneumonia and one patient (160 mg) with nutritional condition abnormal (decreased appetite, fatigue, and vomiting led to significant weight loss)
  - NHL: one patient (640 mg) with pneumonia
- TEAEs led to death in four patients (6.3%)
  - CLL: one patient (640 mg) with pneumonia (related to treatment); one patient (320 mg; related to disease under study) with anemia, platelet count decreased (both related to treatment), and COVID-19 pneumonia (not related to treatment); and one patient (160 mg) with multiple organ failure and hemophagocytic syndrome (both related to treatment)
  - NHL: one patient (640 mg) with pneumonia (not related to treatment)
- No laboratory or clinical TLS was reported
- The maximum tolerated dose was not reached up to 640 mg, and the recommended phase 2 dose was 320 mg once daily

Table 2. TEAE Summary

Patients, n (%)	CLL/SLL (n=29)	NHL (n=35)	All (N=64)
Any TEAE	29 (100)	34 (97.1)	63 (98.4)
Grade ≥3	21 (72.4)	19 (54.3)	40 (62.5)
Serious	16 (55.2)	6 (17.1)	22 (34.4)
Leading to dose interruption	15 (51.7)	5 (14.3)	20 (31.3)
Leading to dose reduction	2 (6.9)	1 (2.9)	3 (4.7)
Leading to treatment discontinuation	2 (6.9)	1 (2.9)	3 (4.7)
Leading to death	3 (10.3)	1 (2.9)	4 (6.3)

Abbreviations: CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; NHL, non-Hodgkin lymphoma; TEAE, treatment-emergent adverse event.

Figure 2. TEAEs in ≥15% of Patients



Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; TEAE, treatment-emergent adverse event..

Antitumor Activity

- In 29 evaluable patients with CLL/SLL and 35 with NHL, overall response rates (ORRs) across dose levels were 72.4% and 20.0%, respectively, and complete response (CR) rates were 31.0% and 8.6% (**Figure 3**)
- Median duration of response was 22.2 months in patients with CLL/SLL and 21.9 months in patients with NHL (**Figure 4**)
- In patients with CLL/SLL, the best rate of undetectable measurable residual disease (uMRD4) in blood was 41.4% (12/29) across doses, with a median time to uMRD of 7.4 months

Figure 3. Response Rates



Abbreviations: CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CR, complete response; NHL, non-Hodgkin lymphoma; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.

Figure 4. Treatment Duration and Investigator-Assessed Responses in Patients With R/R CLL/SLL



Abbreviations: CLL, chronic lymphocytic leukemia; CR, complete response; CRi, complete response with incomplete marrow recovery; NE, not evaluable; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease; SLL, small lymphocytic lymphoma.

REFERENCES

1. Klener P, et al. *Int J Mol Sci*. 2021;22(18):10157-10182.
2. Waggoner M, et al. *J Adv Pract Oncol*. 2022;13(4):400-415.
3. Guo Y, et al. *J Med Chem*. 2024;67(10):7836-7858.
4. Liu J, et al. *Blood*. 2024;143(18):603-608.

DISCLOSURES

ZL, ZS: Employment and may own stock: BeOne Medicines Ltd. **RV:** Employment: BeOne Medicines Ltd; Leadership: Carina Bio; Stock: BeOne Medicines Ltd, AbbVie, Gilead. **CL, KZ, JW, HH, PL, HZ, QC, SY, YD, DW:** Nothing to disclose.

ACKNOWLEDGMENTS

The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating centers. This study was sponsored by BeOne Medicines Ltd. Medical writing was provided by Shanen Perumal, PhD, of Nucleus Global, an Inizio company, and supported by BeOne Medicines.

Presented at the EHA2025 Congress; June 12-15, 2025; Milan, Italy